Table 8.
Lifetime Cost-Effectiveness Results for Subgroups
| Subgroup | Cost with CABG, $ | Cost with PCI, $ | ΔC-P Cost ($) (95% CI) | QALYs with CABG | QALYs with PCI | QALYs Gained with CABG (95% CI) | ICER: Cost ($) per QALY gained | % Dominant | % Dominated | % < $50K |
|---|---|---|---|---|---|---|---|---|---|---|
| Male (n=1,328) | 107,527 | 104,468 | 3,059 (−2,304, 8,406) | 10.856 | 10.078 | 0.778 (0.205, 1.358) | 3,932 | 10.3 | 0.0 | 99.8 |
| Female (n=527) | 131,295 | 122,046 | 9,249 (−729, 18,900) | 10.311 | 9.801 | 0.510 (−0.519, 1.427) | 18,135 | 0.6 | 11.0 | 77.3 |
| Age <60 (n=624) | 136,342 | 125,152 | 11,190 (3,656, 18,572) | 13.897 | 12.737 | 1.160 (0.526, 1.838) | 9,647 | 0.3 | 0.0 | 99.8 |
| Age 60–69 (n=621) | 106,301 | 108,066 | −1,765 (−9,533, 5,504) | 9.947 | 9.671 | 0.276 (−0.486, 0.938) | CABG Dominant | 45.7 | 1.1 | 80.5 |
| Age ≥ 70 (n=610) | 93,926 | 87,034 | 6,892 (−3,018, 15,804) | 6.853 | 6.459 | 0.349 (−0.516, 1.159) | 19,748 | 2.5 | 15.1 | 71.9 |
| SYNTAX Score <23 (n=657) | 113,201 | 104,417 | 8,784 (753, 16,272) | 10.883 | 10.477 | 0.407 (−0.479, 1.180) | 21,582 | 0.3 | 14.7 | 73.5 |
| SYNTAX Score 23–32 (n=828) | 115,602 | 111,441 | 4,160 (−3,670, 11,619) | 10.728 | 9.731 | 0.997 (0.225, 1.699) | 4,172 | 13.7 | 0.1 | 99.2 |
| SYNTAX Score >32 (n=359) | 114,220 | 113,247 | 973 (−10,177, 11,337) | 10.177 | 9.863 | 0.315 (−0.843, 1.373) | 3,088 | 22.9 | 7.3 | 72.4 |
| LAD (n=1,695) | 115,124 | 109,463 | 5,661 (505, 10,981) | 10.713 | 9.991 | 0.722 (0.203, 1.239) | 7,841 | 1.7 | 0.3 | 99.4 |
| No LAD (n=150) | 105,875 | 108,189 | −2,314 (−52,357, 10,225) | 10.126 | 10.239 | −0.112 (−6.933, 1.313) | Not estimable | 18.0 | 8.6 | 43.7 |
| 2 vessel disease (n=310) | 103.264 | 92,313 | 10,950 (−2,486, 21,181) | 11.029 | 10.312 | 0.718 (−1.343, 1.739) | 15,251 | 0.6 | 11.2 | 78.8 |
| 3 vessel disease (n=1,534) | 116,891 | 112,830 | 4,061 (−1,367, 9,483) | 10.634 | 9.937 | 0.697 (0.141, 1.248) | 5,826 | 6.6 | 0.3 | 99.2 |
| HgbA1c < 7 (n=617) | 103,579 | 103,852 | −273 (−6,879, 7,142) | 10.262 | 9.934 | 0.328 (−0.482, 1.132) | CABG Dominant | 34.6 | 2.0 | 80.8 |
| HgbA1c ≥ 7 (n=1,096) | 120,399 | 111,893 | 8,507 (1,618, 15,266) | 11.011 | 10.064 | 0.946 (0.297, 1.547) | 8,993 | 0.5 | 0.4 | 99.5 |
| US (n=351) | 126,113 | 121,412 | 4,701 (−7,997, 17,253) | 10.796 | 9.676 | 1.120 (0.084, 2.033) | 4,197 | 21.8 | 0.3 | 98.1 |
| Non-US (n=1,504) | 111,978 | 106,356 | 5,622 (506, 10,653) | 10.655 | 10.079 | 0.576 (0.006, 1.144) | 9,760 | 1.0 | 2.0 | 96.5 |
*
All subgroup analyses based on mITT population using base case assumptions for the relative effect of CABG on survival and costs